Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics.

Besic N, Satej N, Ratosa I, Horvat AG, Marinko T, Gazic B, Petric R.

BMC Cancer. 2014 Apr 28;14:298. doi: 10.1186/1471-2407-14-298.

2.

[Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].

Zhang HM, Zhang BN, Xuan LX, Zhao P.

Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):447-51. Chinese.

PMID:
19950556
3.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
4.

Association between common risk factors and molecular subtypes in breast cancer patients.

Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K.

Breast. 2013 Jun;22(3):344-50. doi: 10.1016/j.breast.2012.08.005. Epub 2012 Sep 14.

PMID:
22981738
6.

Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.

Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, Ozdemir NY, Zengin N, Altundag K.

J BUON. 2013 Jul-Sep;18(3):608-13.

PMID:
24065471
7.

Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.

Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J.

Tumour Biol. 2014 Mar;35(3):2035-45. doi: 10.1007/s13277-013-1270-5. Epub 2013 Oct 5.

PMID:
24096546
8.

Presenting features of breast cancer differ by molecular subtype.

Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M.

Ann Surg Oncol. 2009 Oct;16(10):2705-10. doi: 10.1245/s10434-009-0606-2. Epub 2009 Jul 11.

PMID:
19593632
9.

Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?

Truong PT, Sadek BT, Lesperance MF, Alexander CS, Shenouda M, Raad RA, Taghian AG.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):57-64. doi: 10.1016/j.ijrobp.2013.09.024. Epub 2013 Oct 22.

PMID:
24161421
10.

Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.

Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, Pérez D, Sáez MI, de Luque V, Medina L, Ramírez-Tortosa CL, Vicioso L, Medina JA, Ribelles N, Alba E.

Oncology. 2012;83(4):228-33. doi: 10.1159/000341537. Epub 2012 Aug 16.

PMID:
22907070
11.

[Clinical features and prognosis analysis of different breast cancer molecular subtypes].

Yang Q, Chen J, Li HJ, Yu M, Tian CX, Lü Q.

Zhonghua Zhong Liu Za Zhi. 2011 Jan;33(1):42-6. Chinese.

PMID:
21575463
12.

Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A.

Breast J. 2013 Jan-Feb;19(1):22-30. doi: 10.1111/tbj.12059. Epub 2012 Dec 13.

PMID:
23240985
13.

Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.

Hattangadi-Gluth JA, Wo JY, Nguyen PL, Abi Raad RF, Sreedhara M, Niemierko A, Freer PE, Georgian-Smith D, Bellon JR, Wong JS, Smith BL, Harris JR, Taghian AG.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1185-91. doi: 10.1016/j.ijrobp.2011.02.061. Epub 2011 May 19.

14.

Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers.

Ibrahim E, Al-Gahmi AM, Zeenelin AA, Zekri JM, Elkhodary TR, Gaballa HE, Fawzy EE, El sayed ME, Alzahrani MS.

Med Oncol. 2009;26(3):372-8. doi: 10.1007/s12032-008-9131-6. Epub 2008 Nov 26.

PMID:
19034706
15.

Prognostic significance of molecular classification of breast invasive ductal carcinoma.

Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J.

Arch Gynecol Obstet. 2009 Jul;280(1):43-8. doi: 10.1007/s00404-008-0867-1. Epub 2008 Dec 11.

PMID:
19082617
16.

Breast-conserving therapy for triple-negative breast cancer.

Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE.

JAMA Surg. 2014 Mar;149(3):252-8. doi: 10.1001/jamasurg.2013.3037.

PMID:
24382582
17.

Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin.

Aksoy S, Sendur MA, Altundag K.

Med Oncol. 2013;30(2):590. doi: 10.1007/s12032-013-0590-z. Epub 2013 May 1.

PMID:
23636908
18.

Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.

García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, González C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Pessarrodona A.

Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.

PMID:
22487206
19.

Clinicopathologic characteristics and prognosis for molecular subtypes in low-grade breast carcinoma: comparison with grade one invasive ductal carcinoma-not otherwise specified.

Wang S, Li W, Liu N, Zhang T, Liu H, Liu J, Liu F, Zhang W, Gebreamlak EP, Niu Y.

Med Oncol. 2012 Dec;29(4):2556-64. doi: 10.1007/s12032-012-0174-3. Epub 2012 Feb 7.

PMID:
22311262
20.

Expression of Basal-like Biomarkers in Triple Negative Invasive Breast Carcinoma in Puerto Rico.

Agosto-Arroyo E, Climent C, Vélez R, Nazario CM, Díaz MV.

P R Health Sci J. 2015 Jun;34(2):89-92.

PMID:
26061059

Supplemental Content

Support Center